Study | Number of FTD patients | Number of ALS patients | Number of FTD and/or ALS patients | Number of controls | Males | Females | Age FTD (years) | Age ALS (years) | Age ALS-FTD (years) | Age control (years) | Pathology in controls | Screening technique | Analysis technique | Risk of bias |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hosokawa et al., 2014 [14] | N/A | 13 | 13 | 7 | 12 | 8 | Ā | 59 | 59 | 49 | GBS | Clinical diagnosis | ELISA | Low |
Noto et al., 2011 [15] | N/A | 27 | 27 | 50 | N/A | N/A | N/A | N/A | N/A | N/A | PD, PSP, MS, MSA, GBS, FS | El Escorial and Awaji | ELISA | Low |
Kasai et al., 2009 [16] | N/A | 30 | 30 | 29 | 19 | 11 | N/A | 65 | 65 | 69 | Nonneurodegenerative/neurological patients and healthy controls | El Escorial | ELISA | Low |
Feneberg et al., 2014 [17] | 4 | 9 | 13 | 8 | 14 | 7 | 66 | 64 | 65 | 62 | Nonneurodegenerative/neurological patients | El Escorial | Western blotting and mass spectrometry | Semiquantitative analysis |
Suarez-Calvet et al., 2014 [20] | 25 | N/A | 25 | 22 | 29 | 18 | 67.8 | N/A | 67.8 | 70.1 | Healthy controls | FTD consensus clinical criteria + CSF biomarker profile to exclude AD. | ELISA compared to manufactured control | No blinding |
Kuiperji et al., 2017 [19] | 36 | N/A | 36 | 21 | N/A | N/A | N/A | N/A | N/A | N/A | Healthy controls | El Escorial | ELISA | Low |
Steinacker et al., 2008 [18] | 24 | 15 | 27 | 13 | 24 | 18 | 68 | 55 | 63 | 60 | Nonneurodegenerative/neurological patients | El Escorial, DSMIV, fMRI, PM lab confirmation | Immunoblot intensity against internal standard | Semiquantitative analysis and concentration compared to single FTD sample |
Total | 77 | 94 | 171 | 150 | 98 | 62 | Medianā=ā67.8 | Medianā=ā61.5 | Medianā=ā65 | Medianā=ā65.5 | N/A | N/A | N/A | N/A |